Diabetogenic Effect of Diet-Induced Obesity among Male Wistar Rats ()
1. Introduction
Data from global population studies present obesity as a major epidemic of the 21st century spreading across developed, emerging, and underdeveloped countries [1] [2]. Reports from the Global Burden of Disease study rank obesity as the 5th leading cause of death—accounting for the death of ~4.7 million (8% of global deaths) in 2017 [3]. This is a marked increase from 4.5% in 1990. The risk of obesity is predicted to rise globally owing to increased global wealth and the availability of processed and high-calorie foods, which are affordable [4] [5]. This proposition is corroborated by observations of increased prevalence of obesity and overweight in lower-middle-income countries in West Africa, including Ghana [6]-[10]. Several risk factors, such as gentrification exposure, age, gender, genetic predisposition, ethnicity, smoking, alcohol consumption, sedentariness, educational level, income, etc., have all been implicated in the cross-links between diabetes and obesity [11]-[15]. In one simulated population-wide study, by adjusting for gender and lifestyle, Nianogo and Arah (2022) reported an increased risk of obesity and T2DM (81%) among adults (18 - 65 years) compared with a relatively lower risk of 31% among children (2 - 17 years) [16] [17]. Even among children, Ganle et al. reported an increased prevalence of obesity with aging. In a cross-sectional study among randomly sampled school children in Ghana, they observed that children aged 11-16 years had six times more risk of becoming obese compared with those in the 5-10 years cohort [10]. In addition, they reported a higher incidence of overweight and obesity among female adolescents than their male counterparts [10].
Pathophysiologically, obesity is a disorder resulting from excessive fat storage in body tissues [18] [19]. It is characterized by elevated body-mass-index (BMI) (>30 kg/m2) in adults, poor quality of life [6], shortened lifespan [6], increased hospitalizations and costs of hospitalizations [7], increased risk to communicable [18] [19] and non-communicable diseases including COVID-19 [8], cancers, coronary artery disease, kidney disease, asthma, stroke, diabetes, decreased reproductive fecundity, among others [8] [18] [20]-[22]. This has been reported to be due to dysregulation of the plasma levels of pro-inflammatory adipokines such as interleukin (IL)-6, tumor necrosis factor (TNF)-α, C-reactive protein (CRP), IL-18, resistin, and visfatin [23] [24] due to increased adipogenesis in obesity. These factors induce oxidative stress, endothelial dysfunction, chronic inflammation, and increased risk of vascular degenerative diseases such as atherosclerosis, myocardial infarction, and hypertension [24]-[28]. Obesity can be categorized as class 1 (low risk) obesity (BMI of 30 to <35), class 2 (moderate risk) obesity (BMI of 35 to <40), and class 3 (high risk) or morbid obesity (BMI of >40) [29]. Prolonged oxidative stress and chronic inflammation due to pancreatic lipotoxicity observed in high-risk and morbid obesity induce mitochondrial damage, endoplasmic reticulum (ER) stress, and beta-cell degeneration, resulting in insulin insufficiency, dysregulated glucose homeostasis, and increased risk of type-2 diabetes [26] [27].
To deal with this emerging pandemic of obesity, there is an urgent need for the development of novel, potent, and effective treatments. This can be achieved by the use of appropriate animal models—human and non-human primates. Diet-induced obesity (DIO) in animal models has the advantages of being cost-effective, polygenic, as in most human obese conditions, and requiring a relatively short time to achieve [30]-[32]. In this study, we induced obesity in male Wistar rats using a high-fat diet (HFD) and measured how this influenced the diabetogenic indices in the rats. This would help us predict the probable pathophysiological cross-link between obesity and diabetes.
2. Materials and Methods
High-Fat Diet Preparation
The high-fat diet (HFD) was formulated by mixing soya-bean oil and melted pork tallow with commercial rat chow at room temperature to provide 31.25% of the total energy from fat. The mixture was stirred to produce dispersed semi-solid pellets and used for feeding animals of the HFD group.
Animal Care and Ethical Considerations
In all, fourty (40) eight-week-old male Wistar rats (180 g ± 15 g) obtained from the Department of Animal Science, Faculty of Agriculture and Natural Resources, Kwame Nkrumah University of Science & Technology (KNUST), were randomly distributed into two equal-sized groups (n = 20). The test group was fed a HFD ad libitum, while the control group was fed a normal rat chow (NFD). The rats were housed in metal cages (five animals per cage) and were maintained at 28˚C ± 2˚C under a cycle of 12 hours of light and 12 hours of darkness, being allowed free access to food and water. The animals were housed and kept under conditions in accordance with the National Institute of Health Guidelines for the care of Laboratory Animals (NIH) (Department of Health Service Publication No. 83-23, revised 1985). All attempts were made to reduce suffering and death among animals used for the study. The dietary treatment lasted for 10 weeks, after which anesthesia was induced in animals following intraperitoneal injection of 0.5 ml of 45 mg/kg BW of pentobarbitone (TCI Ltd, Chou-ku, Tokyo, Japan). Blood and tissue samples were taken for further analysis.
Zoometric Measurements
During the period of dietary treatment, body weight, nose-anal length, body mass index (BMI), changes in weight, and adiposity index were measured weekly. Body weight of rats was measured to the nearest 0.01 g using a digital scale (Shanghai Huachao Industrial Co. Ltd., Shanghai, China), and naso-anal length (to the nearest 0.1cm) using a plastic centimeter ruler (Suzhou Chaosheng Stationery Co. Ltd., Anhui, China). The BMI and adiposity index were determined by calculation from the formula [32]:
kg/m2
cm/g3
Sacrifice
Before the anesthesia, the final body weight of animals in each group was recorded. Anesthesia was achieved by intraperitoneal injection of 1 ml (40 mg/kg body weight) of pentobarbital (Taj Pharmaceutical Ltd., Mumbai, India). About 5 ml of blood was collected by cardiopuncture using disposable syringes (Changzou Standard Medical Devices Co., Xinbei, Changzou, China) into sterile serum separator tubes (Becton, Dickinson and Company, New Jersey, US). The samples were made to stand for 1 hr to clot, after which they were centrifuged (Life Technologies Ltd., Paisley PA4 9RF, UK) at 3000 g for 5 minutes, and the serum was aliquoted into clean Eppendorf tubes and stored at −80˚C to be used for the various biochemical assays.
3. Biochemical Assays
Fasting Blood Glucose, Random Blood Glucose, and Oral Glucose Tolerance
Having fasted for 10 - 12 hrs overnight, the fasting blood glucose (FBG) was determined using a commercially available OneTouch® Glucometer device and its test strips (Lifescan, PA 19355, USA). Using the prick, a puncture was made in the tail capillary, and the blood drop was stained onto a strip inserted into the OneTouch Select glucometer device. The reading on the glucometer was noted. This was repeated for each animal, and the average values were noted for the analysis.
The random blood glucose (RBG) was determined on ordinary days when the animals were not fasting. Just as with FBG described above, the tails of the animals were punctured, and the capillary blood drop was stained onto a strip inserted into the OneTouch® Select glucometer device.
Serum Lipid Profile
The serum total cholesterol (TC), high density lipoprotein (HDL), and triglyceride (TG levels were measured by semi-automated technique using commercially available reagents (Fortress Diagnostics®, Antrim, N. Ireland) and Kenza Max BioChemisTry (Biolabo Diagnostics, Lyon, France). The serum LDL-C, VLDL-C, and HDL-C/LDL-C ratio were determined by calculation, respectively, as follows:
(1)
(2)
NB: Equations (1) and (2) are used when triglyceride is measured in mg/dl.
Fasting Insulin Levels
The serum fasting insulin levels were assayed by enzyme-linked immunosorbent assay (ELISA) technique using a commercially available kit according to the manufacturer’s instructions (Shanghai Chemical Ltd., Shanghai, China) and 10 μl of serum sample [33].
Diabetogenic Indices
The principal diabetogenic indices—homeostatic model assessment of insulin resistance (HOMA-IR), homeostatic model assessment of beta cell function (HOMA-B), homeostatic model assessment of insulin sensitivity (HOMA-S), quantitative insulin sensitivity check index (QUICKI), and disposition index were calculated using the formulae below [19] [33] [34]:
4. Statistical Analysis
The data from the study were analyzed using GraphPad Prism® software version 8.0 (San Diego, California). All data were expressed as mean ± standard deviation. For continuous variables, group differences were determined using the Student t-test or the one-way ANOVA, depending on which was appropriate. The Pearson correlation and logistic regression analysis were used to evaluate the association between biochemical indices, BMI, and diabetes among the experimental animal population after the dietary treatment. From the analysis, all p-values < 0.05 were considered significant.
5. Results and Discussion
Common environmental factors such as prolonged consumption of a diet rich in fat (≥25% w⁄w) have been implicated as a common cause of increased adiposity, whole body insulin resistance (Table 1), β-cell dysfunction, gross obesity, and diabetes mellitus [19] [34]-[39]. The result from our study corroborates this evidence. From our study, most of the rats fed with the HFD over the 10-week period had a significant weight gain (Figures 1(a)-(d)), owing most probably to increased abdominal fat accumulation as observed from Table 2. Common clinical and biochemical presentations of obesity include elevated alanine transaminase levels (AST) [40] due to hepatic steatosis, dyslipidemia [40]-[42], elevated BMI [43], depression [36], decreased adaptive immunity [44] [45]. Obesity, among other things, is also characterized by derangement of nutrient metabolism [46].
Table 1. Composition of diets for experimental rats.
Composition (p/p) |
Normal Rat Chow |
High-Fat Diet (HFD) |
% Weight |
% Weight |
Carbohydrate |
41.475 |
30.500 |
Protein |
18.850 |
17.475 |
Fat/Lipids |
1.975 |
31.250 |
Fibre |
7.700 |
8.350 |
Mineral/Vitamins |
5.625 |
5.325 |
Energy (kCal/kg) |
2590.75 |
4731.50 |
(a)
(b)
(c)
(d)
(e)
(f)
Figure 1. Zoometric measurements of experimental animals. (a) Body weight evaluation; (b) Nose-Anal length changes; (c) Body mass index (BMI) evaluation; (d) Mean change in body weight; (e) Mean change of nose-anal length; (f) Mean change of BMI of Wistar rats after the 10 weeks of dietary treatment. Results are presented as mean ± S.E.M. and n represents the number of animals used in each group. (a) p < 0.05 vs NFD group. (aa) p < 0.01 vs NFD group.
One of the dangers associated with morbid obesity is its negative effect on the functional integrity of the vital organs—liver, lung, heart, kidney, pancreas, and sympathetic nerves [37]. Our findings in Table 2 reveals significantly increased weights of liver, kidney, pancreas, and abdominal fat among the subjects rationed on the HFD compared with those subsisted on the NFD. There have been reports from literature implicating obesity in chronic kidney disease and end-stage renal disease owing to the hyperfiltration resulting in sustained increase in intraglomerular pressure to compensate for the additional metabolic homeostatic demand imposed by the additional body weight [45]. Abdominal fat mass produces pro-inflammatory free fatty acids and adipokines, which infiltrate most visceral organs, causing inflammation of the liver and pancreas [41] [47].
Available evidences reveal that there is a significant decrease in the expression of glucose transporter-4 (GLUT4) in muscles and adipose tissues of obese animals [48] [49]. Another study reported that the translocation, docking, and fusion of GLUT4-containing vesicles with the plasma membrane in adipocytes of obese rats [50]-[52]. Ultimately, these result in impaired insulin sensitivity by various body tissues, hyperinsulinemia, and hyperglycemia among the obese. Even though our results from Table 3 concur with the above findings, it also produces further biomarkers that strengthen the relationship between obesity and diabetes. It shows a marked increase in some common diabetogenic indices, such as HOMA-IR and HOMA-S, with an increase in body weight gain from prolonged dependence on HFD. While hitherto, HOMA-IR as an index is known to be elevated in pathological type 2 diabetes, our findings indicate that it is also elevated in the obese. However, further investigation is required to review the extent of increase in the above index between obesity and type 2 diabetes and to set diametrical cut-off ranges for distinguishing between them. Our study showed a positive correlation between weight gain and HOMA-IR, as has been reported in other studies [38] [39] [53] [54]. On the other hand, there was a negative correlation between weight gain and the other diabetogenic indices, i.e., HOMA-S (r2 = −0.8787, p < 0.0001), HOMA-B (r2 = −0.8805, p < 0.0001), and disposition index (r2 = −0.7827, p < 0.0001) (Table 4 and Figure 2).
Table 2. Morphometric measurements of Wistar rats after 10 weeks of treatment with normal chow and HFD.
Morphometric Indices |
NFD (n = 20) |
HFD (n = 18) |
p-value |
Weight gain (g) |
41.0 ± 5.88 |
83.5 ± 18.4aa |
<0.001 |
Liver weight (g) |
5.68 ± 1.41 |
8.57 ± 3.03a |
<0.01 |
Abdominal fat (g) |
0.43 ± 0.27 |
5.2 ± 1.40a |
<0.0001 |
Adiposity index |
0.28 ± 0.08 |
0.35 ± 0.13a |
0.042 |
Kidney weight (g) |
0.62 ± 0.25 |
1.17 ± 0.08a |
<0.01 |
Pancreas weight (g) |
0.69 ± 0.11 |
1.15 ± 0.45a |
0.027 |
Weight gain/pancreas weight |
36.2 ± 10.49 |
63.3 ± 21.57a |
<0.001 |
Results are presented as mean ± S.E.M. and n represents the number of animals used in each group; the p-values were determined using the unpaired t-test, NFD versus HFD; (a) p < 0.05 was considered significant when compared against the NFD group, (aa) p < 0.01 when compared against the NFD group; NFD: Normal Fed Diet; HFD: High Fat Diet.
Table 3. Biochemical characteristics of study animals.
Biochemical Indices |
BMI (<0.65 g∙cm−2)
(n = 9) |
BMI (0.65≤ BMI ≤ 0.70 g∙cm−2) (n = 16) |
BMI (≥0.71 g∙cm−2) (n = 15) |
p-value |
FBG (mmol/l) |
4.3 ± 0.52 |
4.60 ± 0.28 |
5.5 ± 0.69a |
0.028 |
RBG (mmol/l) |
6.20 ± 0.08 |
6.13 ± 0.45 |
6.7 ± 0.28 |
0.076 |
VLDL-C (mmol/l) |
0.16 ± 0.11 |
0.13 ± 0.08 |
0.30 ± 0.06a |
<0.01 |
Triglyceride (mmol/l) |
0.80 ± 0.17 |
0.65 ± 0.12 |
1.50 ± 0.83a |
<0.01 |
Total Chol. (mmol/l) |
2.46 ± 0.13 |
3.01 ± 0.18 |
4.68 ± 1.70a |
0.035 |
HDL-C (mmol/l) |
1.20 ± 0.60 |
1.50 ± 0.72 |
1.90 ± 0.59 |
0.082 |
LDL-C (mmol/l) |
0.44 ± 0.17 |
1.21 ± 0.05 |
2.10 ± 0.23a |
0.017 |
LDL-C/HDL-C |
0.37 ± 0.04 |
0.81 ± 0.29 |
1.11 ± 0.02a |
0.041 |
TC/HDL-C |
2.05 ± 0.18 |
2.01 ± 0.58 |
2.46 ± 0.73 |
0.069 |
TG/HDL-C |
0.67 ± 0.33 |
0.43 ± 0.11 |
0.79 ± 0.29a |
0.025 |
Fasting Insulin (μU/l) |
10.45 ± 2.71 |
10.68 ± 2.93 |
11.29 ± 3.27 |
0.043 |
HOMA-IR |
2.00 ± 0.69 |
2.18 ± 0.52 |
7.16 ± 1.88a |
<0.001 |
HOMA-B |
268.7 ± 10.84 |
194.18 ± 12.68 |
112.9 ± 5.83a |
<0.001 |
HOMA-S |
50.0 ± 7.31 |
45.90 ± 3.59 |
14.0 ± 1.75a |
<0.001 |
QUICKI |
0.34 ± 0.02 |
0.34 ± 0.17 |
0.33 ± 0.07 |
0.180 |
Disposition Index |
1.34 ± 0.92 |
0.87 ± 0.05 |
0.16 ± 0.10a |
0.037 |
Results are presented as mean ± S.E.M. and n represents the number of animals used in each group; the p-value was determined by the one-way analysis of variance; p < 0.05 was considered significant. (a) p-value < 0.05. Abbreviations: BMI: Body Mass Index; FBG: Fasting Blood Glucose; RBG: Random Blood Glucose; VLDL-c: Very Low Density Lipoprotein Cholesterol; HDL-c: High Density Lipoprotein; LDL-c: Low Density Lipoprotein; TC: Total Cholesterol; TG: Triglyceride; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; HOMA-B: Homeostatic Model Assessment of β-cell Function Index; HOMA-S: Homeostasis Model Assessment of Insulin Sensitivity; QUICKI: Quantitative Insulin Sensitivity Check Index.
Figure 2. Scatter plot showing significant correlations between some diabetogenic indices and BMI among experimental animals used in the study.
Table 4. Logistic linear regression analysis of diabetogenic indices and BMI.
Variable |
p-value |
Odds Ratio |
95% CI |
HOMA-IR |
p < 0.001 |
25.0 |
1.80 - 346.7 |
HOMA-B |
p < 0.01 |
0.1 |
0.0085 - 1.17 |
HOMA-S |
p < 0.01 |
0.89 |
0.047 - 16.66 |
QUCIKI |
p < 0.05 |
1.0 |
0.156 - 6.42 |
Disposition Index |
p < 0.001 |
0.089 |
0.0077 - 1.03 |
6. Limitations of Our Study
The use of laboratory animals as research subjects limits the extrapolation of our findings to humans. Again, the number of animals used poses a statistical constraint on the application of our findings for the management and monitoring of obesity in humans. Nonetheless, our findings were consistent with findings from studies using human subjects. It additionally reveals novel biomarkers that could help further account for the clinical and pathophysiological implications of obesity.
7. Conclusion
Our study reveals that subjects with high BMI have increased insulin resistance and decreased insulin sensitivity and secretion compared with those of lower BMI. Total cholesterol, fasting plasma glucose, fasting plasma insulin, and triglycerides were significantly elevated among subjects with higher BMI. Obesity, therefore, presents itself as a strong risk factor for type 2 diabetes. There is therefore an urgent need for an effective public health policy for the prevention of the epidemic of obesity.
Acknowledgements
The authors hereby acknowledge Mr. Gyan at the Animal House, Department of Pharmacology, Faculty of Pharmacy, KNUST, Ghana, for his technical support in keeping and maintaining the animals used in the study. We also appreciate Mr. Joseph Frempong at the Central Laboratory for his assistance in analyzing the biochemical assays.
Disclaimer
The data and opinions expressed in this paper are new and solely the responsibility of the authors and do not necessarily represent the official views of any auxiliary agencies.
Ethical Consideration
The above study was approved by the Animal Research and Ethics Committee—Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. All conditions and protocols pertaining to animal care and treatments were done in accordance with the National Institute of Health Guidelines for the care of Laboratory Animals (NIH) (Department of Health Service Publication No. 83-23, revised 1985).